Literature DB >> 23183421

Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia.

Kenneth T Bogen1.   

Abstract

Seven current contending cancer theories consider different sets of critical events as sufficient for tumorigenesis. These theories, most recently the microRNA dysregulation (MRD) theory, have overlapping attributes and extensive empirical support, but also some discrepancies, and some do not address both benign and malignant tumorigenesis. By definition, the most efficient tumorigenic pathways will dominate under conditions that selectively activate those pathways. The MRD theory provides a mechanistic basis to combine elements of the current theories into a new hypothesis that: (i) tumors arise most efficiently under stress that induces and sustains either protective or regenerative states of adaptive hyperplasia (AH) that normally are epigenetically maintained unless terminated; and (ii) if dysregulated by a somatic mutation that prevents normal termination, these two AH states can generate benign and malignant tumors, respectively. This hypothesis, but not multistage cancer theory, predicts that key participating AH-stem-cell populations expand markedly when triggered by stress, particularly chronic metabolic or oxidative stress, mechanical irritation, toxic exposure, wounding, inflammation, and/or infection. This hypothesis predicts that microRNA expression patterns in benign vs. malignant tumor tissue will correlate best with those governing protective vs. regenerative AH in that tissue, and that tumors arise most efficiently inmutagen-exposed stem cells that either happen to be in, or incidentally later become recruited into, an AH state.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183421     DOI: 10.1016/j.mehy.2012.10.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  MiR-887-3p Negatively Regulates STARD13 and Promotes Pancreatic Cancer Progression.

Authors:  Xiaobo Xu; Shusen Zheng
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

2.  Mechanistic Models Fit to ED001 Data on >40,000 Trout Exposed to Dibenzo[A,L]pyrene Indicate Mutations Do Not Drive Increased Tumor Risk.

Authors:  Kenneth T Bogen
Journal:  Dose Response       Date:  2014-01-10       Impact factor: 2.658

Review 3.  Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer.

Authors:  Kouji Banno; Yuya Nogami; Iori Kisu; Megumi Yanokura; Kiyoko Umene; Kenta Masuda; Yusuke Kobayashi; Wataru Yamagami; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Mol Sci       Date:  2013-06-06       Impact factor: 5.923

4.  Low-Dose Dose-Response for In Vitro Nrf2-ARE Activation in Human HepG2 Cells.

Authors:  Kenneth T Bogen
Journal:  Dose Response       Date:  2017-05-03       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.